

Title

Immunology Hidradenitis Suppurativa (HS)

Reference Number: RDF2363-24

Date of Response: 14/03/24

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Q1. How many patients does the trust have with a recorded diagnosis of Hidradenitis Suppurativa (HS). 224 Patients.

Q2. Of these patients, how many have been treated with each of the following advanced biologics in the last 6 months?

| Advanced Biologic | Number of HS patients treated in the last 6 months |
|---|---|
| <i>Adalimumab</i> | 35 |
| <i>Infliximab</i> | * <5 |
| <i>Secukinumab</i> | 8 |
| <i>Ustekinumab</i> | * <5 |
| <i>Other advanced biologic/s – please specify name/s:</i> | 0 |

* <5 Section 40 (2)

Please note that in accordance with Section 40 (2) where activity is 5 or less than 5, the Trust is unable to provide the exact information. We consider the data exempt on the following grounds:

The Trust considers that disclosure of the information risks identifying individuals. The reason for this is that the number of patients for which this applies is very low. This and the fact that the data requested relates to the RDUH Health NHS Trust only and therefore relates to patients treated in a specific location (rather than covering a larger geographical area), increases the risk of identification or self-identification.

The Trust's view is that the Section.40(2) Exemption is applicable because disclosure of information which could lead to a patient being identified would be a breach of the patient's rights under the Data Protection Act Data Protection Principles set out in Schedule 1 of the GDPR, namely Principle 1.